1832 Asset Management’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$8.7M Sell
56,957
-2,382
-4% -$365K 0.01% 378
2025
Q4
$8.18M Buy
59,339
+52,139
+724% +$6.83M 0.01% 383
2025
Q3
$923K Buy
7,200
+698
+11% +$85.2K ﹤0.01% 580
2025
Q2
$787K Buy
6,502
+160
+3% +$18K ﹤0.01% 583
2025
Q1
$707K Buy
6,342
+198
+3% +$21.1K ﹤0.01% 581
2024
Q4
$598K Sell
6,144
-212
-3% -$22.6K ﹤0.01% 599
2024
Q3
$731K Buy
6,356
+200
+3% +$22.7K ﹤0.01% 613
2024
Q2
$655K Sell
6,156
-439
-7% -$44.1K ﹤0.01% 604
2024
Q1
$638K Sell
6,595
-3,004
-31% -$308K ﹤0.01% 603
2023
Q4
$969K Buy
9,599
+3,081
+47% +$297K ﹤0.01% 575
2023
Q3
$629K Sell
6,518
-144
-2% -$14.6K ﹤0.01% 603
2023
Q2
$672K Sell
6,662
-4,500
-40% -$450K ﹤0.01% 604
2023
Q1
$1.03M Buy
11,162
+427
+4% +$37.3K ﹤0.01% 590
2022
Q4
$974K Sell
10,735
-1,161
-10% -$97.8K ﹤0.01% 624
2022
Q3
$904K Sell
11,896
-366
-3% -$30.3K ﹤0.01% 616
2022
Q2
$1.04M Sell
12,262
-906
-7% -$79.5K ﹤0.01% 615
2022
Q1
$1.14M Buy
13,168
+189
+1% +$16.4K ﹤0.01% 624
2021
Q4
$1.15M Buy
12,979
+313
+2% +$26K ﹤0.01% 436
2021
Q3
$1.04M Sell
12,666
-725
-5% -$65.2K ﹤0.01% 483
2021
Q2
$1.22M Sell
13,391
-2,702
-17% -$241K ﹤0.01% 460
2021
Q1
$1.31M Sell
16,093
-724
-4% -$65K ﹤0.01% 428
2020
Q4
$1.5M Buy
16,817
+1,267
+8% +$111K ﹤0.01% 474
2020
Q3
$1.26M Buy
15,550
+1,812
+13% +$157K ﹤0.01% 463
2020
Q2
$1.1M Sell
13,738
-51,368
-79% -$4.43M ﹤0.01% 444
2020
Q1
$5.26M Buy
65,106
+53,803
+476% +$4.8M 0.02% 291
2019
Q4
$973K Buy
11,303
+6,465
+134% +$580K ﹤0.01% 431
2019
Q3
$422K Sell
4,838
-422
-8% -$37.9K ﹤0.01% 480
2019
Q2
$480K Sell
5,260
-1,148
-18% -$97.2K ﹤0.01% 502
2019
Q1
$549K Buy
6,408
+295
+5% +$23.7K ﹤0.01% 414
2018
Q4
$471K Sell
6,113
-234
-4% -$18.2K ﹤0.01% 430
2018
Q3
$491K Buy
6,347
+872
+16% +$64.5K ﹤0.01% 476
2018
Q2
$396K Buy
5,475
+345
+7% +$23.8K ﹤0.01% 455
2018
Q1
$371K Sell
5,130
-1,287
-20% -$98K ﹤0.01% 463
2017
Q4
$481K Sell
6,417
-27,781
-81% -$2.1M ﹤0.01% 465
2017
Q3
$2.63M Sell
34,198
-113,464
-77% -$8.57M 0.01% 338
2017
Q2
$11M Sell
147,662
-66,149
-31% -$4.69M 0.05% 242
2017
Q1
$14.2M Sell
213,811
-3,588,700
-94% -$239M 0.05% 225
2016
Q4
$215M Buy
3,802,511
+3,288,029
+639% +$213M 0.36% 70
2016
Q3
$36.4M Buy
514,482
+15,557
+3% +$1.13M 0.14% 153
2016
Q2
$37.1M Buy
498,925
+117,765
+31% +$8.14M 0.14% 143
2016
Q1
$37.9M Sell
381,160
-454,982
-54% -$31M 0.09% 178
2015
Q4
$65.8M Buy
836,142
+208,636
+33% +$16.6M 0.28% 91
2015
Q3
$51.8M Buy
627,506
+81,049
+15% +$7.21M 0.22% 101
2015
Q2
$48M Buy
546,457
+121,373
+29% +$11.1M 0.16% 136
2015
Q1
$37.6M Sell
425,084
-324
-0.1% -$28.7K 0.14% 137
2014
Q4
$35.3M Buy
425,408
+7,924
+2% +$657K 0.11% 160
2014
Q3
$35.2M Buy
417,484
+179,162
+75% +$14.5M 0.12% 166
2014
Q2
$19.3M Buy
238,322
+238,210
+212,688% +$18.7M 0.06% 224
2014
Q1
$9K Sell
112
-28,085
-100% -$2.05M ﹤0.01% 557
2013
Q4
$2.03M Buy
+28,197
New +$1.96M 0.01% 370

Other funds holding NVS

1832 Asset Management's NVS Position: Q1 2026 in Review

1832 Asset Management reduced its Novartis (NVS) stake by 4% in Q1 2026, selling an estimated $365K and leaving 56,957 shares worth $8.7M. The position accounts for 0.01% of the portfolio, ranked #378.

1832 Asset Management first reported a position in NVS in Q4 2013 and has held it in 50 quarters since. The position peaked at $215M in Q4 2016. 1,591 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

  • 1832 Asset Management held 56,957 shares of Novartis worth $8.7M as of Q1 2026.
  • 1832 Asset Management sold 2,382 Novartis shares in Q1 2026, an estimated $365K.
  • Novartis made up 0.01% of 1832 Asset Management's portfolio in Q1 2026, its #378 holding.
  • 1832 Asset Management first reported a position in Novartis in Q4 2013 and has held it in 50 quarters since.
  • 1832 Asset Management's Novartis position peaked at $215M in Q4 2016.
  • 1,591 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on 1832 Asset Management's 13F filing for Q1 2026, filed 14 May 2026.